modafinil has been researched along with Sleep Wake Disorders in 43 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition to its established efficacy for the treatment of cataplexy and EDS, nightly sodium oxybate administration significantly reduces measures of sleep disruption and significantly increases slow-wave sleep in patients with narcolepsy." | 9.14 | The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. ( Black, J; Hornfeldt, CS; Inhaber, N; Pardi, D, 2009) |
| "The purpose of this double-blind, randomized, outpatient study was to evaluate the reinforcing and subjective effects of modafinil (200, 400, or 600 mg) in cocaine abusers." | 9.14 | Modafinil does not serve as a reinforcer in cocaine abusers. ( Foltin, RW; Haney, M; Hart, CL; Rubin, E; Vosburg, SK, 2010) |
| " This multicenter, placebo-controlled study evaluated the efficacy of modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy." | 9.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
| "The authors conducted an open-label trial of modafinil for excessive daytime sleepiness in myotonic dystrophy." | 9.09 | Modafinil for excessive daytime sleepiness in myotonic dystrophy. ( Damian, MS; Gerlach , A; Lehmann , E; Reichmann, H; Schmidt, F, 2001) |
| " Modafinil, a putative central alpha 1 adrenergic agonist, was tested in idiopathic hypersomnia and narcolepsy." | 7.67 | Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. ( Bastuji, H; Jouvet, M, 1988) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 6.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "In addition to its established efficacy for the treatment of cataplexy and EDS, nightly sodium oxybate administration significantly reduces measures of sleep disruption and significantly increases slow-wave sleep in patients with narcolepsy." | 5.14 | The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. ( Black, J; Hornfeldt, CS; Inhaber, N; Pardi, D, 2009) |
| "The purpose of this double-blind, randomized, outpatient study was to evaluate the reinforcing and subjective effects of modafinil (200, 400, or 600 mg) in cocaine abusers." | 5.14 | Modafinil does not serve as a reinforcer in cocaine abusers. ( Foltin, RW; Haney, M; Hart, CL; Rubin, E; Vosburg, SK, 2010) |
| "Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0." | 5.14 | Treatment of sleep disorders after traumatic brain injury. ( Atanasov, S; Castriotta, RJ; Kuna, ST; Lai, JM; Masel, BE; Wilde, MC, 2009) |
| "In patients with MDD who experience sedation as a side effect of antidepressant therapy, adjunctive modafinil improved wakefulness and reduced fatigue." | 5.11 | An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. ( Azhar, N; Cole, K; Hopkins, G; Husain, J; Jones, N; Nihalani, N; Schwartz, TL; Simionescu, M, 2004) |
| " This multicenter, placebo-controlled study evaluated the efficacy of modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy." | 5.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
| "The authors conducted an open-label trial of modafinil for excessive daytime sleepiness in myotonic dystrophy." | 5.09 | Modafinil for excessive daytime sleepiness in myotonic dystrophy. ( Damian, MS; Gerlach , A; Lehmann , E; Reichmann, H; Schmidt, F, 2001) |
| "Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder." | 4.84 | Armodafinil: a new treatment for excessive sleepiness. ( Lankford, DA, 2008) |
| " He was most interested first in patients with disorders of consciousness and secondly in those with sleep/wake disorders, and especially in modafinil for the treatment of patients with narcolepsy and idiopathic hypersomnia." | 3.88 | Michel Jouvet as a clinical neurophysiologist and neurologist. ( Bastuji, H, 2018) |
| "Modafinil (Provigil) was marketed in the UK in 1998 to promote wakefulness in the treatment of narcolepsy." | 3.79 | Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. ( Davies, M; Shakir, S; Wilton, L, 2013) |
| " Modafinil has been found to increase arousal levels in animals and decrease excessive daytime sleepiness in humans." | 3.69 | Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. ( Hendricks, JC; Pack, AI; Panckeri, KA; Schotland, HM, 1996) |
| " Modafinil, a putative central alpha 1 adrenergic agonist, was tested in idiopathic hypersomnia and narcolepsy." | 3.67 | Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. ( Bastuji, H; Jouvet, M, 1988) |
| "Modafinil treatment was associated with a higher mean percentage (52% vs." | 2.82 | Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. ( Angarita, GA; Bessette, A; Canavan, S; Easton, C; Forselius, E; Hodges, S; Malison, RT; McKee, S; Mohsenin, V; Morgan, PT; Oberleitner, L; Pittman, B, 2016) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 2.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness." | 2.75 | Normalizing effects of modafinil on sleep in chronic cocaine users. ( Malison, RT; Morgan, PT; Pace-Schott, E; Pittman, B; Stickgold, R, 2010) |
| "Modafinil-treated participants had a milder withdrawal syndrome as measured by the Amphetamine Cessation Symptom Assessment and less sleep disturbance in comparison to mirtazapine." | 2.73 | Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. ( McGregor, C; Mitchell, A; Srisurapanont, M; White, JM; Wickes, W, 2008) |
| "Two subtypes of narcolepsy have been described (narcolepsy type 1 and narcolepsy type 2), both of which have similar clinical profiles, except for the presence of cataplexy, which occurs only in patients with narcolepsy type 1." | 2.55 | Narcolepsy. ( Dauvilliers, Y; Jennum, PJ; Knudsen, S; Kornum, BR; Ollila, HM; Overeem, S; Pizza, F, 2017) |
| "Clinical trials in these sleep disorders demonstrated an enhanced efficacy for wake promotion (wake sustained for a longer time period using doses lower than those of modafinil)." | 2.44 | Armodafinil for excessive daytime sleepiness. ( Nishino, S; Okuro, M, 2008) |
| "Modafinil is a novel wake-promoting agent that has U." | 2.43 | A systematic review of modafinil: Potential clinical uses and mechanisms of action. ( Ballon, JS; Feifel, D, 2006) |
| "Modafinil also impairs post-sleep deprivation recovery sleep, but from the few studies available addressing this issue, it is unclear whether these sleep impairments translate into post-sleep performance impairments." | 2.43 | Effects of modafinil on cognitive performance and alertness during sleep deprivation. ( Wesensten, NJ, 2006) |
| "Armodafinil is a wake-promoting agent against sleep deprivation related disorders." | 1.62 | Application of armodafinil-loaded microneedle patches against the negative influence induced by sleep deprivation. ( Du, L; Jin, Y; Li, Q; Ou, G; Wang, L; Yu, X; Zhang, S; Zhang, Y; Zhu, L; Zhu, S; Zhuang, X, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 2 (4.65) | 18.2507 |
| 2000's | 24 (55.81) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, L | 1 |
| Zhang, S | 1 |
| Yu, X | 1 |
| Zhu, S | 1 |
| Ou, G | 1 |
| Li, Q | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Zhuang, X | 1 |
| Du, L | 1 |
| Jin, Y | 1 |
| Bastuji, H | 2 |
| Davies, M | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Denlinger, CS | 1 |
| Ligibel, JA | 1 |
| Are, M | 1 |
| Baker, KS | 1 |
| Demark-Wahnefried, W | 1 |
| Friedman, DL | 1 |
| Goldman, M | 1 |
| Jones, L | 1 |
| King, A | 1 |
| Ku, GH | 1 |
| Kvale, E | 1 |
| Langbaum, TS | 1 |
| Leonardi-Warren, K | 1 |
| McCabe, MS | 1 |
| Melisko, M | 1 |
| Montoya, JG | 1 |
| Mooney, K | 1 |
| Morgan, MA | 1 |
| Moslehi, JJ | 1 |
| O'Connor, T | 1 |
| Overholser, L | 1 |
| Paskett, ED | 1 |
| Raza, M | 1 |
| Syrjala, KL | 1 |
| Urba, SG | 1 |
| Wakabayashi, MT | 1 |
| Zee, P | 1 |
| McMillian, NR | 1 |
| Freedman-Cass, DA | 1 |
| Lee, D | 1 |
| Shin, WC | 1 |
| Morgan, PT | 2 |
| Angarita, GA | 1 |
| Canavan, S | 1 |
| Pittman, B | 2 |
| Oberleitner, L | 1 |
| Malison, RT | 2 |
| Mohsenin, V | 1 |
| Hodges, S | 1 |
| Easton, C | 1 |
| McKee, S | 1 |
| Bessette, A | 1 |
| Forselius, E | 1 |
| Chapman, JL | 1 |
| Vakulin, A | 1 |
| Hedner, J | 1 |
| Yee, BJ | 1 |
| Marshall, NS | 1 |
| Kornum, BR | 1 |
| Knudsen, S | 1 |
| Ollila, HM | 1 |
| Pizza, F | 1 |
| Jennum, PJ | 1 |
| Dauvilliers, Y | 1 |
| Overeem, S | 1 |
| Nishino, S | 1 |
| Okuro, M | 1 |
| Cuddy, JS | 1 |
| Reinert, AR | 1 |
| Hansen, KC | 1 |
| Ruby, BC | 1 |
| Hegerl, U | 1 |
| Kantrowitz, J | 1 |
| Citrome, L | 1 |
| Javitt, D | 1 |
| Black, J | 1 |
| Pardi, D | 1 |
| Hornfeldt, CS | 1 |
| Inhaber, N | 1 |
| Bodenmann, S | 1 |
| Rusterholz, T | 1 |
| Dürr, R | 1 |
| Stoll, C | 1 |
| Bachmann, V | 1 |
| Geissler, E | 1 |
| Jaggi-Schwarz, K | 1 |
| Landolt, HP | 1 |
| Vosburg, SK | 1 |
| Hart, CL | 1 |
| Haney, M | 1 |
| Rubin, E | 1 |
| Foltin, RW | 1 |
| Castriotta, RJ | 1 |
| Atanasov, S | 1 |
| Wilde, MC | 1 |
| Masel, BE | 1 |
| Lai, JM | 1 |
| Kuna, ST | 1 |
| Pace-Schott, E | 1 |
| Stickgold, R | 1 |
| Dackis, C | 1 |
| O'Brien, CP | 1 |
| Ortega-Albás, JJ | 1 |
| López-Bernabé, R | 1 |
| Serrano, AL | 1 |
| Díaz, JR | 1 |
| Dasheiff, RM | 1 |
| Crowley, RK | 1 |
| Woods, C | 1 |
| Fleming, M | 1 |
| Rogers, B | 1 |
| Behan, LA | 1 |
| O'Sullivan, EP | 1 |
| Kane, T | 1 |
| Agha, A | 1 |
| Smith, D | 1 |
| Costello, RW | 1 |
| Thompson, CJ | 1 |
| Mahoney, JJ | 1 |
| Jackson, BJ | 1 |
| Kalechstein, AD | 1 |
| De La Garza, R | 1 |
| Chang, LC | 1 |
| Newton, TF | 1 |
| Niepel, G | 1 |
| Bibani, RH | 1 |
| Vilisaar, J | 1 |
| Langley, RW | 1 |
| Bradshaw, CM | 1 |
| Szabadi, E | 1 |
| Constantinescu, CS | 1 |
| Billiard, M | 1 |
| Makela, EH | 2 |
| Miller, K | 1 |
| Cutlip, WD | 1 |
| Douglas, NJ | 1 |
| Schwartz, TL | 1 |
| Azhar, N | 1 |
| Cole, K | 1 |
| Hopkins, G | 1 |
| Nihalani, N | 1 |
| Simionescu, M | 1 |
| Husain, J | 1 |
| Jones, N | 1 |
| Fava, M | 1 |
| Thase, ME | 1 |
| DeBattista, C | 1 |
| Kraft, GH | 1 |
| Bowen, J | 1 |
| Ballon, JS | 1 |
| Feifel, D | 1 |
| Wesensten, NJ | 1 |
| Parmentier, R | 1 |
| Anaclet, C | 1 |
| Guhennec, C | 1 |
| Brousseau, E | 1 |
| Bricout, D | 1 |
| Giboulot, T | 1 |
| Bozyczko-Coyne, D | 1 |
| Spiegel, K | 1 |
| Ohtsu, H | 1 |
| Williams, M | 1 |
| Lin, JS | 1 |
| McGregor, C | 1 |
| Srisurapanont, M | 1 |
| Mitchell, A | 1 |
| Wickes, W | 1 |
| White, JM | 1 |
| Lankford, DA | 1 |
| Panckeri, KA | 1 |
| Schotland, HM | 1 |
| Pack, AI | 1 |
| Hendricks, JC | 1 |
| Damian, MS | 1 |
| Gerlach , A | 1 |
| Schmidt, F | 1 |
| Lehmann , E | 1 |
| Reichmann, H | 1 |
| Teitelman, E | 1 |
| Happe, S | 1 |
| Pirker, W | 1 |
| Sauter, C | 1 |
| Klösch, G | 1 |
| Zeitlhofer, J | 1 |
| Lyons, TJ | 1 |
| French, J | 1 |
| Jouvet, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improvement in Sleep Symptomatology and Neurocognitive Function Using Photobiomodulation in Post-Concussion Patients With Sleep-Wake Disturbances[NCT05072743] | 20 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | |||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
8 reviews available for modafinil and Sleep Wake Disorders
| Article | Year |
|---|---|
Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; | 2016 |
Narcolepsy.
Topics: Adjuvants, Anesthesia; Benzhydryl Compounds; Biomarkers; Cataplexy; Genetic Predisposition to Diseas | 2017 |
Armodafinil for excessive daytime sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; Sle | 2008 |
GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.
Topics: Animals; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Depressants; Central Ner | 2009 |
[Modafinil: pharmacology and therapeutic perspectives].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; | 2003 |
A systematic review of modafinil: Potential clinical uses and mechanisms of action.
Topics: Animals; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; | 2006 |
Effects of modafinil on cognitive performance and alertness during sleep deprivation.
Topics: Arousal; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Dose-Response Relations | 2006 |
Armodafinil: a new treatment for excessive sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Drug and Narcotic Control; Drugs, | 2008 |
15 trials available for modafinil and Sleep Wake Disorders
| Article | Year |
|---|---|
Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence.
Topics: Adult; Benzhydryl Compounds; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modal | 2016 |
Effects of modafinil and sleep loss on physiological parameters.
Topics: Benzhydryl Compounds; Body Temperature; Body Temperature Regulation; Central Nervous System Stimulan | 2008 |
The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Therapy, | 2009 |
The functional Val158Met polymorphism of COMT predicts interindividual differences in brain alpha oscillations in young men.
Topics: Age Factors; Alpha Rhythm; Benzhydryl Compounds; Catechol O-Methyltransferase; Cross-Over Studies; H | 2009 |
Modafinil does not serve as a reinforcer in cocaine abusers.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Choice Behavior; Coc | 2010 |
Treatment of sleep disorders after traumatic brain injury.
Topics: Adult; Benzhydryl Compounds; Benzothiazoles; Brain Injuries; Central Nervous System Stimulants; Diso | 2009 |
Normalizing effects of modafinil on sleep in chronic cocaine users.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; | 2010 |
Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pre | 2011 |
Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.
Topics: Adult; Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Cogni | 2012 |
Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil.
Topics: Adult; Arousal; Autonomic Nervous System; Benzhydryl Compounds; Cardiovascular Agents; Central Nervo | 2013 |
An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder; Diagnostic and | 2004 |
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2005 |
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
Topics: Adult; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Centra | 2008 |
Modafinil for excessive daytime sleepiness in myotonic dystrophy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Humans; Male; Middle Aged; M | 2001 |
Modafinil for narcolepsy.
Topics: Adult; Aged; Ambulatory Care; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Human | 2001 |
20 other studies available for modafinil and Sleep Wake Disorders
| Article | Year |
|---|---|
Application of armodafinil-loaded microneedle patches against the negative influence induced by sleep deprivation.
Topics: Administration, Cutaneous; Animals; Cognition; Drug Delivery Systems; Drug Monitoring; Mice; Microte | 2021 |
Michel Jouvet as a clinical neurophysiologist and neurologist.
Topics: Animals; Cats; Central Nervous System Stimulants; Clinical Competence; Disorders of Excessive Somnol | 2018 |
Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Cohort Studies; D | 2013 |
Survivorship: cognitive function, version 1.2014.
Topics: Adaptation, Psychological; Benzhydryl Compounds; Brain Neoplasms; Central Nervous System Stimulants; | 2014 |
Forced entrainment by using light therapy, modafinil and melatonin in a sighted patient with non-24-hour sleep-wake disorder.
Topics: Actigraphy; Benzhydryl Compounds; Combined Modality Therapy; Female; Humans; Melatonin; Modafinil; P | 2015 |
[Disorders in the regulation of alertness. Drowsy white rock climbing and wide awake at night].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Diagnosis, Differential; Electroencephalogr | 2008 |
Nuvigil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Modafinil | 2009 |
Normalizing effects of modafinil on cocaine-induced sleep abnormalities.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Double- | 2010 |
Sodium oxybate and modafinil: a good combination?
Topics: Benzhydryl Compounds; Drug Interactions; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; | 2010 |
Modafinil is not the new caffeine.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Dose-Response Relationship, Drug; | 2010 |
Three case reports of modafinil use in treating sedation induced by antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Male; | 2003 |
Modafinil and sleepiness.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Humans | 2003 |
New indications for modafinil (Provigil).
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Controlled Clinical Trials as Topic; Dose-R | 2004 |
Dr. Makela replies to Dr. Berigan.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Modafinil; Sleep Wake Disorders | 2004 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder; Diagnostic Errors; Dos | 2005 |
The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Topics: Animals; Benzhydryl Compounds; Brain; Electroencephalography; Histamine; Histamine Agonists; Histami | 2007 |
Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; | 1996 |
Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil.
Topics: Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Humans; Modafinil; Parkinson | 2001 |
Modafinil: the unique properties of a new stimulant.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Sleep Wake Diso | 1991 |
Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil.
Topics: Adrenergic alpha-Agonists; Adult; Benzhydryl Compounds; Disorders of Excessive Somnolence; Female; H | 1988 |